INTRODUCTION
============

Removal of impacted mandibular third molar (M3) is one of the most common performed surgical interventions in dental practice and is often associated with facial swelling, pain and trismus \[[@B1]\]. These postoperative sequelae arise as a result of the natural inflammatory response and often influence the patients' ability to perform their daily activities and compromise the immediate quality of life \[[@B2]\]. Age, gender, medical status, smoking, poor oral hygiene, anatomy, time length of surgical procedure and experience of the surgeon has been associated with an increased risk of postoperative sequelae after surgical removal of M3 \[[@B6]\]. Various treatment modalities have been attempted to prevent or diminish the initial inflammatory response associated with surgical removal of M3 including pharmacological therapies, cryotherapy, local compression and surgical drains \[[@B9]\].

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates \[[@B16]\]. The synthetic analogues of these hormones are the most commonly preferred pharmaceutical agents for decreasing the severity of the natural inflammatory response after surgical removal of M3. Corticosteroids suppress each stage of the initial inflammatory response comprising a decrease in the permeability and capillary dilatation by inhibiting the production of vasoactive substances and reducing the amount of cytokines \[[@B17],[@B18]\]. Moreover, prostaglandin formation is also inhibited by corticosteroids, thereby facilitating some analgesic effects \[[@B19],[@B20]\]. The potential side effects of corticosteroids depend on the intensity and duration of the treatment. Side effects to a single dose of corticosteroids have never been described in oral surgery \[[@B21]\]. Moreover, postoperative infection due to the immunosuppressive effect of corticosteroid has not been observed in oral surgery \[[@B24]\].

Corticosteroids can be administrated systemically or by local injection in the surgical area. Corticosteroids are classiﬁed according to their potency, duration of action, relative mineral corticosteroid and plasma half-life ([Table 1](#T1){ref-type="table"}). Dexamethasone, methylprednisolone and betamethasone are the most commonly administered types of corticosteroids for diminishing the initial inflammatory response after surgical removal of impacted M3. As documented in systematic reviews, various dosages of corticosteroids and durations of treatment as well as different routes of administration have been used revealing dissimilar effects on facial swelling, pain and trismus \[[@B21],[@B25],[@B26]\]. Numerous systematic reviews have concluded that short-term administration of corticosteroids significantly reduces the degree of facial swelling, pain and trismus after surgical removal of impacted M3 \[[@B22],[@B23],[@B25],[@B26]\]. Moreover, parenteral and preoperative prescription of corticosteroids seems to be superior compared to other routes and time of administration \[[@B25]\]. However, many of the included studies disclosed huge heterogeneity, high risk of bias and various confounding variables. Moreover, randomized controlled trials (RCT) comparing different dosages of corticosteroids with similar routes of administration or similar dosage of corticosteroids with different routes of administration are scarce \[[@B23],[@B25]\]. A recent published systematic review and meta-analysis concluded that submucosal injection of dexamethasone significantly diminished facial swelling and pain after surgical removal of impacted M3, whereas no statistically significant difference in trismus was revealed between dexamethasone and placebo \[[@B26]\]. Moreover, an improved outcome for a specific dosage of dexamethasone was not identified in the meta-analysis \[[@B26]\]. These results are in accordance with a newly published systematic review and meta-analysis assessing systematic corticosteroids in orthognathic surgery disclosing that systemic corticosteroids is not supported by strong scientific evidence \[[@B27]\].

###### 

Duration of action and anti-inflammatory potency of corticosteroids

  -----------------------------------------------------------------------------
  Corticosteroid       Duration of\          Anti-inflammatory\   Equivalent\
                       action                potency              dose
  -------------------- --------------------- -------------------- -------------
  Cortisol             Short (\< 12 hours)   1                    20 mg

                                                                  

  Prednisone           Intermediate\         4                    5 mg
                       (12 - 36 hours)                            

                                                                  

  Prednisolone         4                     5 mg                 

                                                                  

  Methylprednisolone   5                     4 mg                 

                                                                  

  Dexamethasone        Long (\> 36 hours)    25                   0.75 mg

                                                                  

  Bethamethasone       25                    0.75 mg              
  -----------------------------------------------------------------------------

Consequently, there seems to be no clear practice consensus regarding the most effective regime for administration of corticosteroids to diminish facial swelling, pain and trismus after surgical removal of impacted M3. Therefore, the objective of the present systematic review was to test the hypothesis of no difference in facial swelling, pain or trismus after surgical removal of impacted M3 with different dosages of corticosteroids and routes of administration.

MATERIAL AND METHODS
====================

**Protocol and registration**

The present systematic review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews \[[@B28]\]. The methods of the analysis, inclusion and exclusion criteria were specified in advance and documented in a protocol. The protocol was registered in PROSPERO, an international prospective register of systematic reviews. It can be accessed at: <https://www.crd.york.ac.uk/PROSPERO/>, with the registration number: CRD42017071955.

**Types of publications**

The review included studies on humans. Letters, editorials, PhD theses, letters to the editor, case reports, abstracts, technical reports, conference proceedings, animal or *in vitro* studies and literature review papers were excluded.

**Types of studies**

The review included all RCT comparing facial swelling, pain and trismus after surgical removal of mandibular M3 with different dosages of corticosteroids or routes of administration.

**Types of outcome measures**

The outcome measures are outlined in [Table 2](#T2){ref-type="table"}.

###### 

Outcome measures

  --------------------------------------------------------------------------------------------------------------------------
  Swelling, evaluated by angles or distances between different reference points of the face
  Pain, evaluated by visual analog scale or consumption of painkillers
  Trismus, evaluated by interincisal distance
  Patient-reported outcome measures and assessment of quality of life, evaluated by questionnaires and visual analog scale
  Complications
  --------------------------------------------------------------------------------------------------------------------------

**Information sources**

The search strategy incorporated examinations of electronic databases, supplemented by a thorough hand-search page by page of relevant journals ([Figure 1](#fig1){ref-type="fig"}). The manual search also included the bibliographies of all articles selected for full-text screening as well as previously published reviews relevant for the present systematic review. Two of the reviewers (MKL, TSJ) performed the search. If disagreements occurred, another reviewer was consulted (TK).

![PRISMA flow diagram demonstrating the results of the systematic literature search.](jomr-09-e1-g001){#fig1}

**Search strategy**

A Medline (Pubmed), Embase and Cochrane Library search was conducted. Human studies published in English until 1^st^ December 2017 were included. The search strategy was performed in collaboration with a medical librarian utilized a combination of Medical subject heading (MeSH) and free text terms. The search strategy is outlined in [Appendix 1 - 3](#app1){ref-type="app"}.

**Selection of studies**

The PRISMA flow diagram presents an overview of the selection process ([Figure 1](#fig1){ref-type="fig"}). The titles of the identified reports were initially screened. The abstract was assessed when the title indicated that the study fulfilled the inclusion criteria. Full-text analysis was carried out when the abstract was unavailable or when the abstract indicated that the inclusion criteria were fulfilled. The references of the identified papers were cross-checked for unidentified articles. The study selection was performed by two reviewers (MKL, TSJ). If disagreements occurred, another reviewer was consulted (TK).

**Study eligibility**

The inclusion criteria were developed using the PICOS guidelines ([Table 3](#T3){ref-type="table"}).

###### 

PICOS guidelines

  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient and population (P)**        All adult healthy patients (\> 15 years) with indications for surgical removal of mandibular third molars.
                                        
  **Intervention (I)**                  Surgical removal of mandibular third molars in conjunction with administration of corticosteroids.
                                        
  **Comparator or control group (C)**   Surgical removal of mandibular third molars with different dosage or administration routes of corticosteroids.
                                        
  **Outcomes (O)**                      Facial swelling, pain, trismus, complications, patient-reported outcome measures, quality of life measures.
                                        
  **Study design (S)**                  Randomized controlled trials in humans with the aim of comparing the postoperative outcome following surgical removal of mandibular third molars with different doses or administration routes of corticosteroids.
                                        
  **Focused question**                  Are there any differences in the postoperative outcome following surgical removal of mandibular third molars with different doses or administration routes of corticosteroids?
  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Inclusion criteria**

Human RCT assessing the treatment outcome following surgical removal of M3 with the use of different dosages or administration routes of corticosteroids were included by addressing the previously described outcome measures. Moreover, at least 20 patients should be included and the surgeon as well as assessors should be blinded. Inclusion and exclusion criteria and the used surgical technique should be clearly specified. In addition, the anatomical location and the surgical difficulty of the impacted M3 should be specified according to a well-known classification system. Moreover, the methods used for assessment of facial swelling, pain and trismus should be useful for statistical analysis.

**Exclusion criteria**

The following exclusion criteria were applied: letters to the editor, case reports, cohort-studies, case-series, retrospective studies, technical reports, conference proceedings, animal or *in vitro* studies and review papers. Moreover, studies with insufficient description of patient selection, surgical procedure, dosage of corticosteroids and administration route as well as studies including medically compromised patients were excluded. Moreover, non-blinded RCT and studies comparing the effects of corticosteroids with other pharmacological therapies or combining corticosteroids with other medications were also excluded.

**Data extraction**

Data were extracted by two of the reviewers (MKL, TSJ) according to a data-collection form ensuring systematic recording of the outcome measures. In addition, relevant characteristics of the study were recorded. The corresponding author was contacted by e-mail in the absence of important information or ambiguities.

**Data items**

The following items were collected from the included studies and arranged in the following fields: authors and year of publication, total number of patients, mean age in year, sex distribution, groups, number of patients in the groups, administration time, route of administration, type of corticosteroid, dosage of corticosteroid, dosage of corticosteroid converted to dosage in dexamethasone, swelling, pain and trismus.

**Assessment of methodological quality**

The quality assessment of the included studies was undertaken by one reviewer (MKL) as part of the data extraction process. The Cochrane Collaboration's tool for assessing risk of bias was used as a methodological quality rating system and the classification of the risk of bias potential for each study was based on seven criteria as outlined in [Table 4](#T4){ref-type="table"} \[[@B29]\].

###### 

Included studies assessing different doses of corticosteroids

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                          Year of\      Patients   Materials and methods   Outcome measures                                                                                 
                                 publication                                                                                                                                       
  ------------------------------ ------------- ---------- ----------------------- ------------------ --- ---- ------- ------ ----- ----------- ----------- ----------- ----------- -----------
  Lim and Ngeow \[30\]           2017          60         25 (SD 4)               11 M;\             A   20   PREOP   S.m.   DEX   4 mg        4 mg        \*\         \*\         \*\
                                                                                  49 F                                                                     A, B \< C   B \< A, C   A, B \< C

                                                                                                                                                                                   

  B                              20            MET        40 mg                   7.5 mg                                                                                           

                                                                                                                                                                                   

  C                              20            \-         0 mg                    0 mg                                                                                             

                                                                                                                                                                                   

  Üstün et al. \[32\]            2003          20         21.9 (SD 2.6)           NM                 A   20   PREOP   i.v.   MET   1.5 mg/kg   0.5 mg/kg   \-          \-          \-

                                                                                                                                                                                   

  B                              20            3 mg/kg    1 mg/kg                                                                                                                  

                                                                                                                                                                                   

  Laureano Filho et al. \[33\]   2008          60         19.5                    30 M;\             A   30   PREOP   Oral   DEX   8 mg        8 mg        \*          \-          \*
                                                                                  30 F                                                                                             

                                                                                                                                                                                   

  B                              30            4 mg       4 mg                                                                                                                     

                                                                                                                                                                                   

  Agostinho et al. \[34\]        2014          27         21.7 (SD 6.4)           10 M;\             A   27   PREOP   Oral   DEX   4 mg        4 mg        \-          \-          \-
                                                                                  17 F                                                                                             

                                                                                                                                                                                   

  B                              27            12 mg      12 mg                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Significant difference between groups, P \< 0.05.

AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; i.v = intravenous; MET = methylprednisolone; N = number of interventions; PREOP = preoperatively; S.m. = submucosal; M = male; F = female.

**Statistical analysis**

Meta-analyses were to be conducted only if there were studies of similar comparison, reporting identical outcome measures. However, the included studies revealed considerable variations in study design, i.e. administration routes, dosages, observation period and postoperative measurements. Therefore, meta-analysis was not applicable. However, the amount of facial swelling and trismus among the included studies were estimated with 95% confidence interval (CI) based on an estimated standard error:

$${SE} = \frac{{sd}_{difference}}{\sqrt{number\ of\ patients}}$$

where the estimated standard deviation (SD) was calculated by:

$${sd}_{difference} = \sqrt{{sd}_{preoperative}^{2} + {sd}_{postoperative}^{2}}$$

The CI were calculated by:

$${lower\ limit} = {mean\ -\ 1.96\ \times\ SE}$$

and

$${upper\ limit} = {mean\ +\ 1.96\ \times\ SE}$$

RESULTS
=======

**Study selection**

Article review and data extraction were performed according to the PRISMA flow diagram ([Figure 1](#fig1){ref-type="fig"}). A total of 800 titles were identified and 525 abstracts were reviewed. Full-text analysis included 18 articles and seven RCT were finally included \[[@B30]\]. One article was included as the result of hand-searching \[[@B36]\].

**Exclusion of studies**

Twelve studies were excluded after full-text assessment. The reasons for excluding the studies were as follow: no blinding or inadequate description of blinding procedure \[[@B15],[@B37]\], less than 20 participants \[[@B46]\] and insufficient description of the surgical procedure \[[@B47]\].

**Study characteristics**

The included studies in the present systematic review consisted of seven hospital-based blinded RCT \[[@B30]\]. Different dosages of corticosteroids were assessed in four studies \[[@B30],[@B32]\]. Different administration routes of corticosteroids were assessed in one study \[[@B36]\], and two studies assessed different dosages and administration routes of corticosteroids \[[@B31],[@B35]\]. Facial swelling, pain and trismus were assessed in all of the included studies, whereas patient-reported outcome measures and quality of life assessment were not reported in any of the included studies. The sample size varied between 20 and 200 patients. A description of the used power calculation of sample size was not reported in any of the included studies. The method used for randomization was described in two studies, involving a random numbers table \[[@B30]\] or opaque envelopes \[[@B31]\]. Age distribution was described in five studies \[[@B31],[@B36]\]. Gender distribution was solely described in three studies \[[@B30],[@B34],[@B36]\]. The surgical experience of the surgeon was reported in two of the included studies \[[@B32],[@B33]\]. The duration of the operations were recorded in five studies \[[@B31],[@B36]\]. Smoking habits among the included patients were not reported in any of the included studies. Different conditions and types of analgesics were used in the included studies. Regular dosages of paracetamol in the postoperative period were prescribed in three studies \[[@B31],[@B33],[@B36]\]. Dosages of 500 mg paracetamol were prescribed in two studies \[[@B31],[@B36]\], and dosages of 750 mg paracetamol were prescribed in one study \[[@B33]\]. Pain was measured in the consumption of analgesics in three studies \[[@B30],[@B32],[@B34]\]. Paracetamol in respective dosages of 500 mg \[[@B32]\] and 750 mg \[[@B34]\] were used in two studies, and 250 mg mefanamic acid was used in one study \[[@B30]\]. The use of postoperative analgesic was not described in one study \[[@B35]\]. Different types and dosages of antibiotics were used in five of the included studies \[[@B30],[@B35],[@B36]\]. Amoxicillin \[[@B36]\] and phenoxymethylpenicillin \[[@B32]\] were prescribed preoperatively in two studies, whereas amoxicillin \[[@B30],[@B31]\] and amoxicillin with clavulanic acid \[[@B35]\] were prescribed postoperatively in three studies. The use of antibiotics were not prescribed in two studies \[[@B33],[@B34]\].

***Different dosages of corticosteroids***

The use of different dosages of corticosteroids after surgical removal of impacted M3 has been assessed in four studies \[[@B30],[@B32]\] ([Table 4](#T4){ref-type="table"}).

Twenty-six patients with symmetrically impacted M3 were random assigned to one hour preoperative intravenous administration of 1.5 mg/kg or 3 mg/kg methylprednisolone in a split-mouth and double-blinded RCT \[[@B32]\]. The impacted M3 were classified according to the Pell and Gregory system with equivalent degree of surgical difficulty \[[@B32]\]. The surgical procedure was separated by three weeks and performed by the same surgeon with patients under local anaesthesia. Facial swelling was evaluated using a tape measuring method described by Gabka and Matsumura \[[@B48]\]. Pain was determined on a daily basis using a questionnaire and a visual analogue scale (VAS). Moreover, the number of analgesics consumed was also registered. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and two and seven days after surgery. A total of six patients were excluded because the questionnaire was not completed properly and the time differences between the surgeries differed more than five minutes \[[@B32]\].

Thirty patients with symmetrically impacted M3 were random assigned to one hour preoperative oral consumption of 4 mg or 8 mg oral dexamethasone in a split-mouth and double-blinded RCT \[[@B33]\]. The impacted M3 were classified according to Winter's classification with similar degree of surgical difficulty \[[@B49]\]. The surgical procedure was separated by fifteen days and performed by the same surgeon with patients under local anaesthesia. Facial swelling was evaluated through facial reference points' variation. Pain was evaluated using a VAS. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and one and two days after surgery. All patients participated in the follow-up examination \[[@B33]\].

Thirty-four patients with symmetrically impacted M3 were random assigned to one hour preoperative oral consumption of 4 mg or 12 mg dexamethasone in a split-mouth and double-blinded RCT \[[@B34]\]. The impacted M3 were classified according to the Pell and Gregory system with similar degree of surgical difficulty \[[@B50]\]. The surgical procedure was separated by fifteen days and performed by the same surgeon with patients under local anaesthesia. Facial swelling was evaluated through facial reference points' variation. Pain was evaluated using a VAS. Moreover, the number of analgesics consumed was also registered. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and one and two days after surgery. A total of seven patients were excluded due to pregnancy and because they did not show up at their postoperative appointments or did not return after the first surgery \[[@B34]\].

Sixty-five patients with symmetrically impacted M3 were random assigned to preoperative submucosal injection of 4 mg dexamethasone, 40 mg methylprednisolone or placebo in a double-blinded RCT \[[@B30]\]. The impacted M3 were classified according to the Pell and Gregory system with similar degree of surgical difficulty \[[@B50]\]. The same surgeon performed the surgical procedure with patients under local anaesthesia. Facial swelling was evaluated through facial reference points' variation. Pain was evaluated using a VAS. Moreover, the number of analgesics consumed was also registered. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and one, two, five and seven days after surgery. No information of drop-outs or withdrawals was provided \[[@B30]\].

***Different administration routes of corticosteroids***

Different administration routes of corticosteroids after surgical removal of impacted M3 have been assessed in one study \[[@B36]\].

Twenty patients with symmetrically impacted M3 were random assigned to one hour preoperative oral consumption of 8 mg oral dexamethasone or intramuscular injection (deltoid muscle) of 8 mg dexamethasone in a split-mouth and double-blinded RCT \[[@B36]\]. The impacted M3 were classified according to their horizontal angulation with similar degree of surgical difficulty but no classification system was specified. The surgical procedure was separated by one month and performed by the same surgeon with patients under local anaesthesia. Facial swelling was evaluated by different facial reference points/landmarks. Pain was evaluated using VAS. Moreover, the number of analgesics consumed was also registered. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and one, three and seven days after surgery. No information of drop-outs or withdrawals was provided \[[@B36]\].

***Different dosages and administration routes of corticosteroids***

Different dosages and administration routes of corticosteroids after surgical removal of impacted M3 have been assessed in two studies \[[@B31],[@B35]\].

Forty-three patients were allocated to endo-alveolar administration of 4 mg or 10 mg dexamethasone or submucosal injection 10 mg dexamethasone in a split-mouth and double-blinded RCT \[[@B35]\]. The impacted M3 were classified according to the Pell and Gregory system with similar degree of surgical difficulty \[[@B50]\]. The surgical procedure was separated by at least four weeks and performed by the same surgeon with patients under local anaesthesia. Facial swelling was evaluated by different facial reference points'/landmarks. Pain was evaluated using VAS. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and two and seven days after surgery. No information of drop-outs or withdrawals was provided \[[@B35]\].

Two hundred patients with symmetrically impacted M3 were random assigned to one hour preoperative oral consumption of 8 mg dexamethasone or intravenous administration of 4 mg dexamethasone in a split-mouth and double-blinded RCT \[[@B31]\]. The impacted M3 were classified according to the Pell and Gregory system with similar degree of surgical difficulty according to Pederson's Index \[[@B50]\]. The surgical procedure was separated by two weeks and performed with patients under local anaesthesia. No information was provided about the number of surgeons. Facial swelling was evaluated using facial reference points' variation according to Neupert et al. \[[@B51]\]. Pain was evaluated using VAS. Moreover, the number of analgesics consumed was also registered. Trismus was determined by measuring maximum interincisal opening. Assessment of facial swelling and trismus were obtained before surgical intervention and one, two and seven days after surgery. A total of five patients did not participate in the study follow-up period for unreported reason \[[@B31]\].

The main results are described below and summarized in [Tables 4 - 6](#T4){ref-type="table"}.

###### 

Included studies assessing different administration routes of corticosteroids

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Year of\      Patients   Materials and methods   Outcome measures                                                          
                               publication                                                                                                                
  ---------------------------- ------------- ---------- ----------------------- ------------------ --- ---- -------- ------ ----- ------ ------ ---- ---- ----
  Boonsiriseth et al. \[36\]   2012          20         20                      3 M; 17 F          A   20   POSTOP   I.m.   DEX   8 mg   8 mg   \-   \-   \-

                                                                                                                                                          

  B                            20            Oral       8 mg                    8 mg                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; I.m. = intramuscular; N = number of interventions; POSTOP = postoperatively; M = male; F = female.

###### 

Included studies assessing different doses and administration routes of corticosteroids

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                     Year of\      Patients   Materials and methods   Outcome measures                                                                    
                            publication                                                                                                                          
  ------------------------- ------------- ---------- ----------------------- ------------------ --- ----- -------- ------ ----- ------ ------ -------- --------- ----------
  Chaudhary et al. \[31\]   2015          200        20.8                    NM                 A   100   PREOP    i.v.   DEX   4 mg   4 mg   \-       \-        \-

                                                                                                                                                                 

  B                         100           Oral       8 mg                    8 mg                                                                                

                                                                                                                                                                 

  Graziani et al. \[35\]    2006          43         24 (SD 4)               13 M; 30 F         A   15    POSTOP   E.a.   DEX   4 mg   4 mg   \*\      \*\       \*\
                                                                                                                                              A, B,\   A \<\     A, B \<\
                                                                                                                                              C \< D   B, C, D   C, D

                                                                                                                                                                 

  B                         14            E.a.       10 mg                   10 mg                                                                               

                                                                                                                                                                 

  C                         14            S.m.       4 mg                    4 mg                                                                                

                                                                                                                                                                 

  D                         43            \-         0 mg                    0 mg                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Significant difference between groups, P \< 0.05.

AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; E.a. = endo-alveolar; i.v. = intravenous; N = number of interventions; NM = not mentioned; POSTOP = postoperatively; PREOP = preoperatively; S.m. = submucosal; M = male; F = female.

**Quality assessment**

The quality of the included studies is summarized in [Table 7](#T7){ref-type="table"}. A low risk of bias was found in two studies \[[@B30],[@B35]\]. Unclear risk of bias was found in five studies, since the randomization method was not described \[[@B31],[@B36]\].

###### 

Quality assessment of included studies using Cochrane Collaboration's tool \[29\]

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Study                          Sequence\    Allocation\   Blinding of\     Blinding of\   Incomplete\   Selective\   Other\        Study\
                                 generation   concealment   participants,\   outcome\       outcome\      outcome\     sources of\   quality of\
                                                            personnel        assessors      data          reporting    bias          bias
  ------------------------------ ------------ ------------- ---------------- -------------- ------------- ------------ ------------- --------------
  Lim and Ngeow \[30\]           Yes          Yes           Yes              Yes            Yes           Yes          Yes           Low risk

                                                                                                                                     

  Chaudhary et al. \[31\]        Unclear      Unclear       Yes              Yes            Yes           Yes          Yes           Unclear risk

                                                                                                                                     

  Üstün et al. \[32\]            Unclear      Unclear       Yes              Yes            Yes           Yes          Yes           Unclear risk

                                                                                                                                     

  Laureano Filho et al. \[33\]   Unclear      Unclear       Unclear          Yes            Yes           Yes          Yes           Unclear risk

                                                                                                                                     

  Agostinho et al. \[34\]        Unclear      Unclear       Yes              Yes            Yes           Yes          Yes           Unclear risk

                                                                                                                                     

  Graziani et al. \[35\]         Yes          Yes           Yes              Yes            Yes           Yes          Yes           Low risk

                                                                                                                                     

  Boonsiriseth et al. \[36\]     Unclear      Unclear       Yes              Yes            Yes           Yes          Yes           Unclear risk
  -------------------------------------------------------------------------------------------------------------------------------------------------

**Outcome measures**

The result of each outcome measure is presented first and then a short summary is finally provided. All the reported numerical values are presented as mean values. Patient-related outcome measures were not reported in any of the included studies and therefore not described below or in [Tables 4 - 6](#T4){ref-type="table"}. The amount of facial swelling and trismus among the included studies is present in [Figure 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

![Facial swelling (mm) with different dosages of dexamethasone and administration routes.\
CI = confidence interval; i.m. = intramuscular; i.v. = intravenous.](jomr-09-e1-g002){#fig2}

![Trismus (mm) with different dosages of dexamethasone and administration routes.\
CI = confidence interval; i.m. = intramuscular; i.v. = intravenous.](jomr-09-e1-g003){#fig3}

**Facial swelling**

Different dosages of corticosteroids disclosed no significant differences in facial swelling at any time points after preoperative intravenous administration of 1.5 mg/kg methylprednisolone compared with 3 mg/kg, submucosal injection of 40 mg methylprednisolone compared with 4 mg dexamethasone and oral consumption of 4 mg dexamethasone compared with 12 mg, respectively \[[@B30],[@B32],[@B34]\]. However, a significant diminished facial swelling was reported after oral consumption of 8 mg dexamethasone compared with 4 mg, one and two days after surgery \[[@B33]\]. Moreover, submucosal injection of 40 mg methylprednisolone or 4 mg dexamethasone revealed significant diminished facial swelling compared with placebo \[[@B30]\].

Different administration routes of corticosteroids disclosed no significant differences in facial swelling at any time points after preoperative oral consumption of 8 mg dexamethasone compared with intramuscular injection of 8 mg dexamethasone \[[@B36]\].

Different dosages and administration routes of corticosteroids disclosed no significant differences in facial swelling at any time points after intravenous administration of 4 mg dexamethasone compared with oral consumption of 8 mg dexamethasone \[[@B31]\]. Endo-alveolar application of 4 mg and 10 mg dexamethasone and submucosal injection of 4 mg dexamethasone significantly diminished facial swelling compared to placebo \[[@B35]\].

In summary, preoperative submucosal injection of corticosteroids seems to diminish facial swelling compared to placebo after surgical removal of impacted M3. However, there seems to be no difference in facial swelling with dissimilar dosage of corticosteroids or route of administration, although oral consumption of 8 mg dexamethasone disclosed significant diminished facial swelling compared with 4 mg during the first postoperative days \[[@B33]\]. The degree of facial swelling in the abovementioned studies is outlined in [Figure 2](#fig2){ref-type="fig"}.

**Pain**

Different dosages of corticosteroids disclosed no significant differences in pain at any time points after preoperative intravenous administration of 1.5 mg/kg methylprednisolone compared with 3 mg/kg, oral consumption of 4 mg dexamethasone compared with 8 mg and oral consumption of 4 mg dexamethasone compared with 12 mg, respectively \[[@B32]\]. However, significant reduced pain was reported after submucosal injection of 40 mg methylprednisolone compared with 4 mg dexamethasone, one, two, five and seven days after surgery \[[@B30]\]. Moreover, submucosal injection of 40 mg methylprednisolone or 4 mg dexamethasone revealed significant diminished pain compared with placebo \[[@B30]\].

Different administration routes of corticosteroids disclosed no significant differences in pain at any time points after preoperative oral consumption of 8 mg dexamethasone compared with intramuscular injection of 8 mg dexamethasone \[[@B36]\].

Different dosages and administration routes of corticosteroids disclosed no significant differences in pain at any time points after intravenous administered of 4 mg dexamethasone compared with oral consumption of 8 mg dexamethasone \[[@B31]\]. However, endo-alveolar application of 4 mg dexamethasone revealed significantly diminished pain compared with endo-alveolar application of 10 mg dexamethasone or submucosal injection of 4 mg dexamethasone, after two and seven days \[[@B35]\].

In summary, preoperative submucosal injection of corticosteroids seems to reduce postoperative pain compared with placebo after surgical removal of impacted M3. Moreover, endo-alveolar application of corticosteroids compared with submucosal injection seems to significantly diminish postsurgical pain. However, endo-alveolar application with a higher dosage of corticosteroids seems not to proportionally reduce pain after removal of impacted M3.

**Trismus**

Different dosages of corticosteroids disclosed no significant differences in trismus at any time points after preoperative intravenous administration of 1.5 mg/kg methylprednisolone compared to 3 mg/kg, submucosal injection of 40 mg methylprednisolone compared to 4 mg dexamethasone, and oral consumption of 4 mg dexamethasone compared to 12 mg, respectively \[[@B30],[@B32],[@B34]\]. However, a significant diminished trismus was reported after oral consumption of 8 mg dexamethasone compared to 4 mg, one and two days after surgery \[[@B33]\]. Moreover, submucosal injection of 40 mg methylprednisolone or 4 mg dexamethasone revealed significant diminished trismus compared to placebo \[[@B30]\].

Different administration routes of corticosteroids disclosed no significant differences in trismus at any time points after preoperative oral consumption of 8 mg dexamethasone compared to intramuscular injection of 8 mg dexamethasone \[[@B36]\].

Different dosages and administration routes of corticosteroids disclosed no significant differences in trismus at any time points after intravenous administered of 4 mg dexamethasone compared to oral consumption of 8 mg dexamethasone \[[@B35]\]. Endo-alveolar application of 4 mg dexamethasone or 10 mg dexamethasone reveal significantly reduced trismus at any time points compared to submucosal injection of 4 mg dexamethasone \[[@B31]\].

In summary, preoperative submucosal injection of corticosteroids seems to reduce postoperative trismus compared with placebo after surgical removal of impacted M3. Moreover, endo-alveolar application compared with submucosal injection seems to decrease trismus. However, the use of a higher dosage of corticosteroids seems not to proportionally diminish trismus after removal of impacted M3. The degree of trismus in the abovementioned studies is outlined in [Figure 3](#fig3){ref-type="fig"}.

**Complications**

Complications were not described in three studies \[[@B31],[@B33],[@B36]\] and no complications were reported in two studies \[[@B30],[@B35]\]. One study excluded patients with complications and did not describe the number or the degree of complications \[[@B34]\]. Mild nausea was described in one patient after six days \[[@B32]\].

In summary, complications related to preoperative administration of corticosteroids in conjunction with surgical removal of M3 seem to be negligible.

DISCUSSION
==========

The objective of the present systematic review was to test the hypothesis of no difference in facial swelling, pain and trismus after surgical removal of impacted M3 with different dosages of corticosteroid and routes of administration. A total of seven RCT were included in the present systematic review \[[@B30]\]. Two studies were considered low risk of bias \[[@B30],[@B35]\], whereas five studies were considered unclear risk of bias \[[@B31],[@B36]\]. Preoperative submucosal injection of corticosteroids significantly diminishes facial swelling, pain and trismus compared with placebo \[[@B30]\]. However, different dosages of corticosteroid and routes of administration reveal contrary results indicating that administration of a higher dosage of corticosteroids do not necessarily cause a proportionally decrease in facial swelling, pain and trismus. Moreover, the included studies revealed considerable heterogeneity in patient demographic, study design as well as evaluation methods, outcome measures and posed various methodological confounding factors, which yield serious restrictions to review the literature in a quantitative systematic manner. Hence, the conclusions drawn from the results of this systematic review had to be cautiously interpreted.

Preoperative administration of corticosteroids significantly diminishes facial swelling compared with placebo after surgical removal of M3, which has previously been documented in systematic reviews and meta-analyses \[[@B21],[@B25]\]. These results are in accordance with the results of the present systematic review. The included studies of the present systematic review used two-dimensional linear \[[@B30],[@B32],[@B35],[@B36]\] or angle \[[@B31],[@B33],[@B34]\] measurements for assessment of the postoperative facial swelling. The validity and reliability of quantifying volume changes in facial morphology by using two-dimensional imaging are limited and associated with significant ambiguity. Two-dimensional measurements lack appropriate facial depth and shape \[[@B52],[@B53]\]. Three-dimensional facial optical scanning technique improves measurement accuracy and has previously been used for assessment of facial swelling after surgical removal of impacted M3 using two different cooling therapy methods and low-level laser therapy, treatment of zygomatic fractures and in orthognathic surgery \[[@B54]\]. Moreover, a study with three-dimensional photogrammetry reported that 4 mg dexamethasone significantly reduced facial swelling after surgical removal of mandibular M3 compared to placebo \[[@B59]\]. Conversely, a newly published RCT using three-dimensional photogrammetry demonstrated that 15 mg dexamethasone did not further reduce postoperative facial swelling compared with 5 mg in orthognathic surgery \[[@B24]\]. Hence, further RCT assessing the influence of corticosteroids on facial swelling after surgical removal of impacted M3 should include standardized three-dimensional facial scanning measurements.

Anti-inflammatory analgesic also reduces tissue swelling after surgical removal of M3. Dissimilar dosages and brands of postoperative analgesics were administered in the included studies, which presumably influence the degree of postoperative facial swelling \[[@B60]\]. Thus, further RCT assessing the influence of corticosteroids on postoperative facial swelling after surgical removal of M3 should include a standardized analgesics protocol.

Pain is the most common complication following surgical removal of M3, which may affect or impair the patient's immediate quality of life and habits. The pain relief effect of corticosteroids is presumably due to the inhibitory effect on prostaglandin formation and diminished postsurgical facial swelling \[[@B18]\]. Preoperative administration of corticosteroids significantly diminishes postoperative pain compared with placebo after surgical removal of impacted M3, which has been documented in systematic reviews and meta-analyses \[[@B1],[@B25]\]. These results are in accordance with the results of the present systematic review. However, the reduction in pain with the use of corticosteroids disclosed contradictory results among the included studies of the present systematic review \[[@B30]\]. A significant improved pain relief was obtained with endo-alveolar application of corticosteroids compared with submucosal injection, whereas a higher dosage of corticosteroids seemed not to proportionally reduce pain after surgical removal of impacted M3. All of the included studies measured pain with VAS \[[@B30]\], which is one of the best known and commonly preferred scale to measure pain \[[@B61]\]. Other pain assessment methods as verbal rating scale and full cup test have also been used after surgical removal of M3 \[[@B61]\]. However, these assessment methods do not distinguish between pain tolerance or expectation \[[@B8]\]. Furthermore, three studies measured pain with the consumption of analgesics \[[@B30],[@B32],[@B34]\]. The type and dosage of analgesics varied between the studies. Two studies used paracetamol in different dosages \[[@B32],[@B34]\], and one study used mefanamic acid \[[@B30]\]. However, analgesics in regular dosages in the postoperative period were prescribed in three studies \[[@B31],[@B33],[@B36]\], and the use of postoperative analgesics was not described in one study \[[@B35]\]. Consequently, the reduction in pain can be related to the analgesics and not to the use of corticosteroids.

Pain assessment after surgical removal of impacted M3 may be influenced by objective and subjective factors including surgical trauma, duration of surgery and experience of the surgeon as well as anxiety, pain tolerance or pain expectation \[[@B8],[@B62]\]. In addition, the sociocultural background may also have an effect on the pain level \[[@B63]\]. Standardization of the surgical technique, duration of the surgical procedure and experienced of the surgeon was described in some of the included studies of the present systematic review, whereas none of the included studies evaluated patients' anxiety, pain tolerance or expectation. Thus, further RCT assessing the influence of corticosteroids on pain after surgical removal of impacted M3 should include a standardized postoperative protocol and assessment of anxiety, pain tolerance or expectation.

Postsurgical trismus caused by facial swelling, pain, hematoma or inflammation may interfere with the patients' ability to eat, speak and maintaining proper oral hygiene. Preoperative administration of corticosteroids seems to reduce trismus compared with placebo after surgical removal of impacted M3, as documented in previous published systematic reviews and meta-analyses \[[@B21],[@B25]\]. However, a newly published meta-analysis disclosed no significant difference in trismus between corticosteroids and placebo \[[@B26]\]. These conflicting results are in accordance with the results of the present systematic review. Mandibular range of motion is commonly measured with maximum opening, left lateral, right lateral and protrusive movement. Jaw range of motion scale, TheraBite^®^ (Atos Medical, Hörby, Sweden) range of motion scale and interincisal maximal mouth opening are different measurement tools to determine opening, lateral and protrusive mandibular range of motion \[[@B64],[@B65]\]. TheraBite^®^ range of motion scale is a reproducible and valid mouth opening measurement tool using a cardboard scale \[[@B65]\]. Linear measurements of interincisal maximal mouth opening before and after surgical removal of impacted M3 is a simple, reliable, reproducible and validated method for assessment of postsurgical trismus, which has been used in all of the included studies of the present systematic review.

Several factors may influence postoperative sequelae after surgical removal of impacted M3 including systemic medical conditions, smoking, oral hygiene, physical activity, surgical trauma, duration of surgery and experience of the surgeon \[[@B6],[@B7]\]. A newly published retrospective study reported that dry socket was the most common complication after M3 extraction and the overall prevalence of postsurgical complications was 17% \[[@B66]\]. It has previously been documented in a retrospective study, that partially impacted teeth reveal the highest incidence of complications and cigarette smoking correlated with an increased complication rate and dry sockets \[[@B66]\]. The included studies of the present systematic review excluded medically compromised patients and smoking habits was not reported in any of the included studies \[[@B30]\]. However, the percentage of dry socket was not described in any of the included studies and complications were only reported in one study involving mild nausea \[[@B32]\].

Prolonged use of corticosteroids may interfere with the natural wound healing process and increase the risk of infection due to an inhibiting effect on the body's inflammatory response \[[@B17],[@B18]\]. However, increased risk of postsurgical infection related to a single dosage of corticosteroid has never previously been reported and none of the included studies of the present systematic review described side effects related to the dosage of corticosteroids or the route of administration.

Patient-reported outcome measures are essentially subjective reports of patient perceptions of their oral health status and its impact on their daily life or quality of life. The Oral Health Impact Profile Questionnaire (OHIP), Orofacial Esthetic Scale and Chewing Function Questionnaire are standardised methods commonly used for the assessment of patient-reported outcome measures. Health-related quality of life measures are valid and reflect the severity of a disease and how it affects or impairs a patient's life. None of the included studies in the present systematic review used patient-reported outcome measures for assessment of the final treatment outcome. However, OHIP-14 and other questionnaires have previously been used to assess patient-reported outcome measures after surgical removal of impacted M3 revealing that administration of corticosteroids improve the immediate quality of life \[[@B39],[@B67]\]. A RCT showed that submucosal injection and oral consumption of prednisolone were associated with less deterioration in quality of life compared to placebo after surgical removal of M3 \[[@B39]\]. Furthermore, significantly better quality of life was seen in patients receiving prednisolone into submucosa compared to oral consumption \[[@B39]\]. Consequently, further RCT assessing the treatment outcome after surgical removal of M3 with administration of corticosteroids should include standardized patient-reported outcome measures.

Corticosteroids can be administered before, during or after surgical removal of M3. None of the included studies in the present systematic review focused on the time of administration. Five studies administered it preoperatively \[[@B30]\], whereas two studies administered it postoperatively \[[@B35],[@B36]\]. Preoperatively administered methylprednisolone has previously shown deterioration in postoperative swelling, pain and trismus compared to postoperatively administered corticosteroid \[[@B68]\]. However, postoperatively administered dexamethasone has provided less postoperative pain compared to preoperative administration \[[@B69]\]. Consequently, further RCT assessing the treatment outcome after surgical removal of M3 with different time of administration of corticosteroids should be performed.

To summarise, preoperative administration of corticosteroids significantly reduces the degree of facial swelling, pain and trismus after surgical removal of impacted M3 \[[@B22],[@B23],[@B25],[@B26]\]. From a clinical and patient perspective, it would be an advantage to use the least dose of corticosteroids and submucosal injection compared to other routes of administration. However, the optimal dosage and route of administration with the highest effect on facial swelling, pain and trismus is presently unknown. Moreover, preoperative administration of corticosteroids in mandibular M3 surgery should be individualized and only prescribed in cases where moderate postoperative pain and swelling is expected.

CONCLUSIONS
===========

The hypothesis of no difference in facial swelling, pain or trismus after surgical removal of impacted mandibular third molar with different dosages of corticosteroids and routes of administration could neither be confirmed nor rejected due to insufficient knowledge. Preoperative submucosal injection of corticosteroids significantly diminishes facial swelling, pain and trismus compared with placebo. However, different dosages of corticosteroids and administration routes reveal contrary results indicating that administration of a higher dosage of corticosteroids do not necessarily cause a proportionally decrease in facial swelling, pain and trismus. Consequently, the optimal dosage of corticosteroids and administration route for diminishing postsurgical morbidity and improve the immediate quality of life after surgical removal of mandibular third molar is presently unknown. Therefore, further well-designed randomized clinical trials including a standardised protocol, larger patient sample, patient-reported outcome measures and three-dimensional analysis of facial swelling is needed.
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